News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
261,799 Results
Type
Article (13950)
Company Profile (304)
Press Release (247545)
Section
Business (79358)
Career Advice (151)
Deals (13191)
Drug Delivery (34)
Drug Development (50332)
Employer Resources (31)
FDA (5682)
Job Trends (5116)
News (144139)
Policy (10018)
Tag
Academia (901)
Alliances (21529)
Alzheimer's disease (760)
Approvals (5665)
Artificial intelligence (69)
Bankruptcy (97)
Best Places to Work (4522)
Biotechnology (249)
Breast cancer (110)
Cancer (894)
Cardiovascular disease (71)
Career advice (132)
CAR-T (73)
Cell therapy (217)
Clinical research (40151)
Collaboration (311)
Compensation (129)
COVID-19 (1007)
C-suite (79)
Cystic fibrosis (67)
Data (986)
Diabetes (87)
Diagnostics (1207)
Drug discovery (57)
Earnings (29007)
Events (47199)
Executive appointments (249)
FDA (6055)
Funding (310)
Gene editing (63)
Gene therapy (163)
GLP-1 (311)
Government (1065)
Healthcare (6545)
Infectious disease (1045)
Inflammatory bowel disease (98)
IPO (7200)
Job creations (859)
Job search strategy (127)
Layoffs (188)
Legal (1375)
Lung cancer (131)
Lymphoma (62)
Manufacturing (87)
Medical device (2560)
Medtech (2561)
Mergers & acquisitions (6131)
Metabolic disorders (262)
Neuroscience (1006)
NextGen Class of 2024 (2004)
Non-profit (847)
Northern California (1096)
Obesity (142)
Opinion (91)
Parkinson's disease (78)
Patents (63)
People (25109)
Phase I (14157)
Phase II (18669)
Phase III (11821)
Pipeline (367)
Postmarket research (851)
Preclinical (5971)
Radiopharmaceuticals (205)
Rare diseases (204)
Real estate (1410)
Regulatory (8289)
Research institute (931)
Southern California (983)
Startups (1964)
United States (8717)
Vaccines (165)
Weight loss (84)
Date
Last 7 days (146)
Last 30 days (1319)
Last 365 days (20564)
2024 (20528)
2023 (22413)
2022 (26822)
2021 (27805)
2020 (23357)
2019 (16224)
2018 (11738)
2017 (13745)
2016 (11839)
2015 (14349)
2014 (10392)
2013 (7484)
2012 (7532)
2011 (7614)
2010 (7428)
Location
Africa (146)
Asia (16929)
Australia (2856)
California (2488)
Canada (817)
China (206)
Colorado (93)
Connecticut (104)
Europe (36452)
Florida (273)
Georgia (71)
Illinois (154)
Indiana (61)
Maryland (336)
Massachusetts (1961)
Michigan (58)
Minnesota (101)
New Jersey (635)
New York (692)
North Carolina (420)
Northern California (1096)
Ohio (82)
Pennsylvania (478)
South America (207)
Southern California (983)
Texas (282)
Washington State (249)
261,799 Results for "phosplatin therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Pharm Country
Phosplatin Therapeutics Adopts New Corporate Name as Promontory Therapeutics Inc.
Phosplatin Therapeutics Inc. today announced that the Company has changed its name to Promontory Therapeutics Inc.
May 5, 2022
·
2 min read
Pharm Country
Phosplatin Therapeutics Announces $37 Million Series A Financing
Phosplatin Therapeutics Inc. today announced that it has completed a $37 million Series A financing.
December 14, 2021
·
4 min read
Business
Phosplatin Therapeutics Appoints Sebastian Guth, PhD, to Board of Directors
Phosplatin Therapeutics Inc., a clinical stage pharmaceutical company focused on oncology therapeutics, today announced the appointment of Sebastian Guth, PhD, to the company’s Board of Directors.
January 4, 2022
·
3 min read
Business
Phosplatin Therapeutics Appoints Lorenzo Galluzzi, PhD, a Pioneer in Immunogenic Cell Death Research, to Scientific Advisory Board
Phosplatin Therapeutics Inc., a clinical stage pharmaceutical company focused on oncology therapeutics, today announced the appointment of Lorenzo Galluzzi, PhD, to the company’s Scientific Advisory Board.
March 24, 2022
·
4 min read
Business
Phosplatin Therapeutics Appoints Industry Veteran Elizabeth Tallett to Board of Directors
Phosplatin Therapeutics Inc. today announced the appointment of Elizabeth Tallett to the company’s Board of Directors.
September 29, 2021
·
3 min read
Drug Development
Phosplatin Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of PT-112 for Thymoma and Thymic Carcinoma in Collaboration with National Cancer Institute
Phosplatin Therapeutics Inc. today announced the first patient has been treated in a Phase 2 clinical trial of the company’s lead therapeutic candidate, PT-112.
April 13, 2022
·
5 min read
Pharm Country
Phosplatin Therapeutics to Present at 2021 BIO Digital
Phosplatin Therapeutics Inc. announced today that it has been selected to deliver a presentation on the development program of its lead candidate, PT-112, an immunogenic cell death (ICD) inducer, at 2021 BIO Digital, the premier biotech event.
June 10, 2021
·
4 min read
Pharm Country
Phosplatin Therapeutics Reports on PT-112’s Selective Effects and Immunogenic Cell Death in Human Prostate Cancer Cell Models at the AACR Annual Meeting 2022
Phosplatin Therapeutics Inc., a clinical stage pharmaceutical company focused on small molecule immunogenic therapies in oncology, reported today new non-clinical data on its lead candidate, PT-112, at the American Academy of Cancer Research (AACR) Annual Meeting 2022.
April 11, 2022
·
5 min read
Business
Phosplatin Therapeutics Collaborates with the National Cancer Institute For Phase 2 Proof of Concept Study of PT-112 in Thymoma and Thymic Carcinoma
Phosplatin Therapeutics Inc., a clinical stage pharmaceutical company focused on oncology therapeutics, today announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), part of the National Institutes of Health.
November 15, 2021
·
5 min read
Pharm Country
Phosplatin Therapeutics Presents on PT-112 at the 2022 AACR Annual Meeting: Selective Intracellular Effects Leading to Immunogenic Cell Death (ICD) in Prostate Cancer Cell Models
Phosplatin Therapeutics Inc., a clinical stage pharmaceutical company focused on oncology therapeutics, today announced an in-person poster presentation will be given at the American Academy of Cancer Research (AACR) on its lead candidate, PT-112, and how it selectively induces potent mitochondrial stress and immunogenic cell death in human prostate cancer cell lines.
March 10, 2022
·
4 min read
1 of 26,180
Next
